Skip to main content

Preeclampsia Diagnostics Market worth USD 2.52 Billion at 11.0% CAGR by 2027; Increasing Healthcare Expenditure to Boost Growth: Fortune Business Insights™

Written by Customer Service on . Posted in Mergers And Acquisitions.

Pune, Aug. 24, 2020 (GLOBE NEWSWIRE) — The global preeclampsia diagnostics market is anticipated to gain momentum from the increasing number of pregnancies owing to the complete lockdown amid the COVID-19 pandemic. This information is given by Fortune Business Insights™ in a new report, titled, “Preeclampsia Diagnostics Market Size, Share & COVID-19 Impact Analysis, By Test Type (Blood Tests and Urine Analysis), By Product (Instruments and Consumables) End-user (Hospitals, Specialty Clinics, Diagnostic Centers, and Others) and Regional Forecast, 2019-2027.” The report further states that this market size was USD 1.06 billion in 2019 and is projected to reach USD 2.52 billion by 2027, thereby exhibiting a CAGR of 11.0% during the forecast period.What are the challenges and opportunities in the market?What are the market dynamics, hindrances, and growth drivers?What are the estimated, present, and historical sizes of the global market?What steps are being taken by companies to surge sales of preeclampsia diagnosis kits?Drivers & Restraints-Increasing Prevalence of Preeclampsia in Developing Nations to Boost GrowthThe increasing perinatal and maternal morbidity & mortality rate is set to surge the need for the early diagnosis of preeclampsia worldwide among pregnant women. The British Charity Action on Pre-eclampsia (APEC) declared that in the U.K. every year, around 7 mothers die on account of complications related to preeclampsia and approximately 1000 babies die owing to the same cause. The condition is majorly affecting the health of both neonates and mother, especially in the emerging countries. As per the BMC Journal, in Africa, preeclampsia affects around 10% of pregnant women annually. These factors are set to propel the preeclampsia testing market growth in the coming years.The outbreak of the COVID-19 pandemic has caused an unprecedented demand in the healthcare industry. Presently, because of the unavailability of efficient healthcare facilities and midwives, the cases of cancelled or delayed abortions have surged rapidly. Besides, the number of coronavirus positive cases amongst pregnant women is increasing, which, in turn, is resulting in the high demand for preeclampsia diagnostics. We are providing elaborate research reports to help you better understand the effects of this pandemic on every pandemic.Instruments Segment to Grow Rapidly Owing to Their Highly Sensitive Nature Based on product type, the market is bifurcated into consumables and instruments. Out of these, the instruments segment is expected to grow significantly throughout the forthcoming period because of their highly sensitive nature. They are extensively used for fast and accurate testing for preeclampsia. Regional Analysis-High Pregnancy Rate to Drive Growth in Asia PacificIn 2019, North America generated USD 401.9 million in terms of preeclampsia screening market revenue. This growth is attributable to the significant healthcare expenditure and the rising usage of technologically advanced preeclampsia diagnostics kits in this region. Coupled with this, the increasing awareness programs amongst the patients and doctors regarding the severity of the disease would propel growth in this region. Asia Pacific, on the other hand, is expected to remain in the second position after North America backed by the increasing adoption of fertility treatments, high rate of pregnancy, and the rising population.Key Players Aim to Introduce Wide Product Offerings to Intensify CompetitionThe market for preeclampsia diagnostics consists of several prominent companies that are persistently trying to gain a competitive edge by introducing a wide range of product offerings. Some of them are also trying to broaden their geographical footprint by expanding their brand presence. Below are two of the latest industry developments:February 2019: Diabetomics introduced a rapid point-of-care test called Lumella in Hyderabad. It is a novel preeclampsia diagnosis test.March 2019: The Ohio State University Wexner Medical Center introduced its latest urine test for preeclampsia diagnosis at an early stage.
Fortune Business Insights™ lists out the names of all the renowned preeclampsia diagnostics providers operating in the global market. They are as follows:F. Hoffmann-La Roche Ltd (Basel, Switzerland)PerkinElmer Inc. (Massachusetts, United States)DRG INSTRUMENTS GMBH (HE, Germany)Thermo Fisher Scientific Inc. (Massachusetts, United States)Diabetomics, Inc. (Massachusetts, United States)Metabolomic Diagnostics Ltd. (Munster, Ireland)Sera Prognostics (UT, United States)Siemens Healthineers AG (Erlangen, Germany)Bayer AG (Leverkusen, Germany)OthersIntroductionResearch ScopeMarket SegmentationResearch MethodologyDefinitions and AssumptionsExecutive SummaryMarket DynamicsMarket DriversMarket RestraintsMarket OpportunitiesKey InsightsPrevalence of Preeclampsia by Key RegionsPricing Analysis by Key Players in Major RegionsTechnological Advancements in Preeclampsia DiagnosticsNew Test Type Launch by Key PlayersKey Industry Developments – Partnerships, Mergers, and AcquisitionsGlobal Preeclampsia Diagnostics Market Analysis, Insights and Forecast, 2016-2027Key Findings / SummaryMarket Analysis, Insights and Forecast – By Test TypeBlood TestsUrine AnalysisMarket Analysis, Insights and Forecast – By ProductInstrumentsConsumablesMarket Analysis, Insights and Forecast – By End UserHospitalsSpecialty ClinicsDiagnostic CentersOthersMarket Analysis, Insights and Forecast – By RegionNorth AmericaEuropeAsia PacificLatin AmericaMiddle East & AfricaTOC Continued…!!!
Preeclampsia Therapeutics Market Share & Industry Analysis, By Preeclampsia Type (Mild Preeclampsia, Severe Preeclampsia), By Drug Class (Antihypertensive Agents, Anticonvulsants, Antioxidants, Others) and Regional Forecast, 2019-2026Immunodiagnostics Market Share and Global Trend By Product Instruments, Reagents & Consumables), By Application (Oncology & Endocrinology, Hepatitis & Retrovirus, Cardiac Markers, Infectious Diseases), By End user (Clinical Laboratories, Hospitals, Physician’s Offices), By End-user(Hospitals, Dental Clinics, Academic & Research Institutes) and Geography Forecast till 2026Point of Care (POC) Diagnostics Market Share and Global Trend By Product (Blood Glucose Monitoring, Infectious Diseases, Cardiometabolic Diseases, Pregnancy and Fertility Testing Products, Hematology Testing Products, Others), By End User (Hospitals Bedside, Physician’s Office Lab, Urgent Care & Retail Clinics, Home and Self Testing) and Geography Forecast till 2026Molecular Diagnostics Market Share and Global Trend By Product Type (Instruments Reagents & Consumables), Application (Infectious Disease, Blood Screening, Histology & Oncology), Technique (Hospitals Amplification, Hybridization & Sequencing Techniques), End User (Hospitals, Clinical & Pathology Labs) and Geography Forecast till 2025In-vitro Diagnostics (IVD) Market Share & Industry Analysis, By Product Type (Instruments, Reagents & Consumables), By Technique (Immunodiagnostics, Clinical Chemistry, Molecular Diagnostics, Point of Care, Hematology and Others), By Application (Infectious Diseases, Cardiology, Oncology, Gastroenterology, Others), By End User (Clinical Laboratories, Hospitals, Physicians Offices, Others) and Regional Forecast, 2019 – 2026
About Us:Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.Contact Us:Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/preeclampsia-diagnostics-market-9457

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.